Treatment Of Patients With Metastatic Melanoma And Renal Cancer With A Combination Of Flt3L And CD40L

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed metastatic renal cell cancer or melanoma
Measurable disease

PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-1 Life expectancy:
More than 3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least
90,000/mm3 No coagulation disorders Hepatic: Bilirubin no greater than 1.6 mg/dL AST and
ALT less than 2.5 times normal Hepatitis B surface antigen negative Renal: Creatinine no
greater than 2.0 mg/dL Cardiovascular: No major active medical illness of the
cardiovascular system (e.g., cardiac ischemia, myocardial infarction, or cardiac
arrhythmia) Pulmonary: No major active medical illness of the respiratory system (e.g.,
obstructive or restrictive pulmonary disease) Other: Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception No active systemic
infections No history of autoimmune disorders HIV negative

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy
No prior systemic flt3 ligand or CD40-ligand Chemotherapy: At least 3 weeks since prior
chemotherapy Endocrine therapy: At least 3 weeks since prior endocrine therapy No
concurrent systemic steroids Radiotherapy: Prior localized radiotherapy for renal cell
cancer or melanoma allowed Surgery: Prior surgery for renal cell cancer or melanoma
allowed